BioSpace News Archive

BrainStorm Cell Therapeutics Inc. announced that it will be presenting at the Dawson James Securities 5th Annual Small Cap Growth Conference, being held on October 28-29, 2019 at the Wyndham Grand Hotel in Jupiter, Florida.

Recently, Fountain Medical Development Limited announced its $62 mm Series D round financing.

Insulet Corporation, the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, announced FDA clearance for use of Fiasp® with the Omnipod® Insulin Management System and the Omnipod DASH™ Insulin Management System for adults.

Anixa Biosciences, Inc., a biotechnology company focused on harnessing the body’s immune system in the fight against cancer, announced its collaboration with Urology San Antonio, PA in Anixa’s ongoing Cchek™ prostate cancer study.

Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that it will report financial results for the quarter ended September 30, 2019 and host a conference call at 4:30 PM Eastern Time on Thursday, November 7, 2019.

Universal Health Realty Income Trust (NYSE:UHT) announced today that for the three-month period ended September 30, 2019, reported net income was $4.7 million, or $.34 per diluted share, as compared to $4.4 million, or $.32 per diluted share, during the third quarter of 2018.

Allergan plc announced that its Board of Directors has declared a cash dividend of $0.74 per ordinary share for the fourth quarter of 2019.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the company was once again ranked as a top company to work for by Science magazine in its annual Top Employers Survey of the global biotech and pharmaceutical industry.

MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the first patient has been dosed in the Phase 2/3 MAHOGANY clinical trial of margetuximab, an investigational, Fc-optimized monoclonal antibody targeting HER2

TCI Co., Ltd. was invited to join the 11th Anniversary of Climate Week NYC, one of the top global forums focusing on global climate action.